Strata Critical Medical, Inc.
5.80%
5,126,511
1779128
Oct 12, 2026
Oct 15, 2026, 04:09 PM
Reporting Persons (2)
This is a joint filing. The reported shares may overlap between reporting persons and should not be summed.
| Name | Type | % of Class | Aggregate | Sole Voting | Shared Voting |
|---|---|---|---|---|---|
| Third Point LLC | Other | 5.80% | 5,126,511 | 0 | 5,126,511 |
| Loeb Daniel S | Individual | 5.80% | 5,126,511 | 0 | 5,126,511 |
Disclosure Items (7)
Common Stock, par value $0.0001 per share
Strata Critical Medical, Inc.
666 Third Avenue, New York, NY, 10017
This Schedule 13D is being filed by the Reporting Persons.
The principal business address of the Reporting Persons is 55 Hudson Yards, 51st Floor, New York, New York 10001.
The principal business of the Management Company is to serve as investment manager or adviser to a variety of hedge funds and managed accounts (such funds and accounts, collectively, the "Funds"), and to control the investing and trading in securities of the Funds. The principal occupation of Mr. Loeb is serving as Chief Executive Officer of the Management Company.
During the last five years, none of the Reporting Persons have been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree, or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.
The Management Company is organized as a limited liability company under the laws of the State of Delaware. Mr. Loeb is a citizen of the United States of America.
The Funds expended an aggregate of $24,452,374 of their own investment capital to acquire the 5,126,511 shares of Common Stock held by them. The Reporting Persons and Funds may effect purchases of shares of Common Stock through margin accounts maintained for them with brokers, which extend margin credit as and when required to open or carry positions in their margin accounts, subject to applicable federal margin regulations, stock exchange rules and such firms' credit policies. Positions in shares of Common Stock may be held in margin accounts and may be pledged as collateral security for the repayment of debit balances in such accounts. Such margin accounts may from time to time have debit balances. In addition, since other securities may be held in such margin accounts, it may not be possible to determine the amounts, if any, of margin used to purchase shares of Common Stock.
On the date of this Schedule 13D, the Reporting Persons may be deemed to beneficially own an aggregate of 5,126,511 shares of Common Stock of the Issuer representing approximately 5.8% of the outstanding shares of Common Stock of the Issuer. Calculations of the percentage of shares of Common Stock beneficially owned assume 88,466,806 shares of Common Stock outstanding as of July 28, 2026, as reported in the Issuer's Quarterly Report on Form 10-Q filed on August 4, 2026.
Each of the Reporting Persons shares voting and dispositive power over the shares of Common Stock held directly by the Funds. See rows 7 through 10 of the cover pages of this Schedule 13D for the number of shares of Common Stock as to which each Reporting Person has sole or shared power to vote or direct the vote and sole or shared power to dispose or direct the disposition.
Exhibit 99.3 filed herewith, which is incorporated herein by reference, describes all transactions in the shares of Common Stock effected during the past sixty days by the Reporting Persons, inclusive of any transactions effected through 4:00 p.m., New York City time, on October 15, 2026.
Other than the Funds that directly hold the shares of Common Stock, and except as set forth in this Item 5, no other person is known to have the right to receive, or the power to direct the receipt of, dividends from or proceeds from the sale of, the shares of Common Stock.
Not applicable.
The information contained in Items 3, 4 and 5 is incorporated by reference herein, as applicable. Joint Filing Agreement On October 15, 2026, the Reporting Persons entered into a Joint Filing Agreement pursuant to which they agreed to the joint filing on behalf of each of them of this Schedule 13D (and any amendments thereto) with respect to the securities of the Issuer. Such Joint Filing Agreement is filed herewith as Exhibit 99.1 and is incorporated herein by reference.
99.1 Joint Filing Agreement, dated October 15, 2026, by and between Third Point LLC and Daniel S. Loeb. 99.2 Power of Attorney granted by Daniel S. Loeb in favor of Jana Tsilman and Joshua L. Targoff, dated February 9, 2024, which was previously filed with the SEC on February 13, 2024 as Exhibit 99.2 to the Schedule 13G/A filed by Third Point LLC and Daniel S. Loeb with respect to Global Blue Group Holding AG and is incorporated herein by reference. 99.3 Trading Data.